Back
ESC Professional Premium Access

Aficamten in patients with obstructive hypertrophic cardiomyopathy: an integrated safety analysis

Session: Novel therapies for hypertrophic cardiomyopathy: recent developments and future prospects
Topic: Hypertrophic Cardiomyopathy
Speaker: Doctor A. Masri (Portland, US)
Event: ESC Congress 2024

Congress Presentation

Add to my library

Like

About the speaker

Doctor Ahmad Masri

Oregon Health & Science University Medical Group, Portland (United States of America)
18 presentations
1 follower

4 more presentations in this session

State-of-the-art lecture on novel therapies for hypertrophic cardiomyopathy: recent developments and future prospects

Speaker: Doctor C. Ho (Boston, US)

Access
Slides
Video
Like
Thumbnail

Long-term safety and efficacy of mavacamten in obstructive hypertrophic cardiomyopathy: up to 3.5-year follow-up results of the EXPLORER cohort of MAVA-Long-Term Extension study

Speaker: Doctor P. Garcia-Pavia (Majadahonda, ES)

Access
Abstract
Slides
Video
Like
Thumbnail

Clinical application of biomarkers in obstructive hypertrophic cardiomyopathy: insights from SEQUOIA-HCM

Speaker: Doctor C. Coats (Glasgow, GB)

Access
Abstract
Slides
Video
Like
Thumbnail

Effect of trimetazidine dihydrochloride therapy on myocardial external efficiency in preclinical individuals with an HCM sarcomeric gene mutation

Speaker: Mr B. Van Driel (Amsterdam, NL)

Access
Abstract
Slides
Video
Like
Thumbnail

Access the full session

Novel therapies for hypertrophic cardiomyopathy: recent developments and future prospects

Speakers: Doctor A. Masri, Doctor C. Ho, Doctor P. Garcia-Pavia, Doctor C. Coats, Mr B. Van Driel
Access
Video
Like
Thumbnail

About the event

Image

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

bristol-myers-squibb Explore sponsored resources
novartis Explore sponsored resources